Chin Richard 4

What Happened

• Richard Chin, a director of Cytek Biosciences (CTKB), had 6,107 restricted stock units convert to 6,107 shares on March 10, 2026 (reported as a derivative conversion/exercise, code M). The filing also shows a simultaneous disposition of 6,107 shares at $0.00. No cash purchase or sale proceeds are reported.
• This was not a market purchase or cash sale. Converting RSUs to shares and showing a $0.00 disposition is commonly used for net share settlement or to satisfy tax-withholding obligations, rather than an open-market sale.

Key Details

• Transaction date: March 10, 2026; Form 4 filed March 12, 2026.
• Reported transactions: 6,107 shares acquired via conversion/exercise (derivative); 6,107 shares disposed at $0.00 (derivative).
• Price/value: Acquired price listed as N/A; disposed price listed as $0.00 (no cash proceeds reported).
• Shares owned after transaction: Not disclosed in the filing.
• Footnotes: F1 — each RSU converts to one share; F2 — this transaction reflects the vesting schedule (3/36 of the award vested on March 10, 2026).

Context

• These were RSU conversions (not option purchases). When converted RSUs are immediately reported as disposed at $0.00, it typically indicates net settlement or withholding to cover taxes rather than an active market sale. Such transactions are routine for vested equity awards and do not necessarily signal a change in insider sentiment.